The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma

Gouji Toyokawa, Kenichi Taguchi, Makoto Edagawa, Shinichiro Shimamatsu, Ryo Toyozawa, Kaname Nosaki, Fumihiko Hirai, Masafumi Yamaguchi, Mototsugu Shimokawa, Takashi Seto, Mitsuhiro Takenoyama, Ryuji Hamamoto, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Background: Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. Patients and Methods: Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. Results: Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. Conclusion: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.

Original languageEnglish
Pages (from-to)4841-4846
Number of pages6
JournalAnticancer research
Issue number9
Publication statusPublished - Sept 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this